Literature DB >> 1694582

Disposition characteristics of macromolecules in tumor-bearing mice.

Y Takakura1, T Fujita, M Hashida, H Sezaki.   

Abstract

As part of the strategy for the design of macromolecular carriers for drug targeting, the disposition characteristics of macromolecules were studied in mice bearing tumors that served as target tissues. Eight kinds of macromolecules including four polysaccharides and four proteins with different molecular weights and electric charges were used; tissue distribution and tumor localization after intravenous injection were studied. Pharmacokinetic analysis revealed that the tissue radioactivity uptake rate index calculated in terms of clearance was different among the tested compounds; especially, the urinary radioactivity excretion clearances and the total hepatic radioactivity uptake clearances varied widely. Compounds with low molecular weights (approximately 10 kD) or positive charges showed lower tumor radioactivity accumulation; radioactivity was rapidly eliminated from the plasma via rapid urinary excretion or extensive hepatic uptake, respectively. On the other hand, large and negatively charged compounds, carboxymethyl dextran, bovine serum albumin, and mouse immunoglobulin G, showed higher radioactivity accumulation in the tumor (calculated total amounts were 15.6, 10.8, and 20.8% of the dose, respectively) and prolonged retention in the circulation. These results demonstrated that the total systemic exposure rather than the uptake rate index was correlated with total tumor uptake. Molecular weight and electric charge of the macromolecules significantly affected their disposition characteristics and, consequently, determined radioactivity accumulation in the tumor. It was concluded that a drug-carrier complex designed for systemic tumor targeting should be polyanionic in nature and larger than 70,000 in molecular weight.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1694582     DOI: 10.1023/a:1015807119753

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  30 in total

1.  Cellular interaction and in vitro antitumor activity of mitomycin C-dextran conjugate.

Authors:  S Matsumoto; A Yamamoto; Y Takakura; M Hashida; N Tanigawa; H Sezaki
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

2.  Disposition of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate, in the perfused rat liver.

Authors:  K Sato; K Itakura; K Nishida; Y Takakura; M Hashida; H Sezaki
Journal:  J Pharm Sci       Date:  1989-01       Impact factor: 3.534

3.  Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport.

Authors:  A K Kumagai; J B Eisenberg; W M Pardridge
Journal:  J Biol Chem       Date:  1987-11-05       Impact factor: 5.157

4.  Animal scale-up.

Authors:  R L Dedrick
Journal:  J Pharmacokinet Biopharm       Date:  1973-10

5.  Disposition and pharmacokinetics of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate, in the rat.

Authors:  M Hashida; A Kato; Y Takakura; H Sezaki
Journal:  Drug Metab Dispos       Date:  1984 Jul-Aug       Impact factor: 3.922

6.  The preparation and labeling of DTPA-coupled albumin.

Authors:  D J Hnatowich; W W Layne; R L Childs
Journal:  Int J Appl Radiat Isot       Date:  1982-05

7.  The accumulation mechanism of cationic mitomycin C-dextran conjugates in the liver: in-vivo cellular localization and in-vitro interaction with hepatocytes.

Authors:  S Nakane; S Matsumoto; Y Takakura; M Hashida; H Sezaki
Journal:  J Pharm Pharmacol       Date:  1988-01       Impact factor: 3.765

8.  Fluid endocytosis by rat liver and spleen. Experiments with 125I-labelled poly(vinylpyrrolidone) in vivo.

Authors:  J Munniksma; M Noteborn; T Kooistra; S Stienstra; J M Bouma; M Gruber; A Brouwer; D Praaning-van Dalen Dalen; D L Knook
Journal:  Biochem J       Date:  1980-11-15       Impact factor: 3.857

9.  Covalent linkage of carboxypeptidase G2 to soluble dextrans--II. In vivo distribution and fate of conjugates.

Authors:  R G Melton; C N Wiblin; A Baskerville; R L Foster; R F Sherwood
Journal:  Biochem Pharmacol       Date:  1987-01-01       Impact factor: 5.858

10.  Enhanced lymphatic delivery of mitomycin C conjugated with dextran.

Authors:  Y Takakura; S Matsumoto; M Hashida; H Sezaki
Journal:  Cancer Res       Date:  1984-06       Impact factor: 12.701

View more
  39 in total

Review 1.  Pharmaceutical strategies utilizing recombinant human serum albumin.

Authors:  Victor Tuan Giam Chuang; Ulrich Kragh-Hansen; Masaki Otagiri
Journal:  Pharm Res       Date:  2002-05       Impact factor: 4.200

Review 2.  Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins.

Authors:  Iftekhar Mahmood; Martin D Green
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver.

Authors:  K Nishida; K Mihara; T Takino; S Nakane; Y Takakura; M Hashida; H Sezaki
Journal:  Pharm Res       Date:  1991-04       Impact factor: 4.200

Review 4.  Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution.

Authors:  Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

Review 5.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

6.  A complementary strategy for enhancement of nanoparticle intracellular uptake.

Authors:  Yingjia Li; Ge Wen; Dongxiao Wang; Xia Zhang; Yaoyong Lu; Jianguo Wang; Lijuan Zhong; Hongbing Cai; Xingmei Zhang; Ying Wang
Journal:  Pharm Res       Date:  2014-02-21       Impact factor: 4.200

7.  Validation of the chloramine-T induced oxidation of human serum albumin as a model for oxidative damage in vivo.

Authors:  Makoto Anraku; Ulrich Kragh-Hansen; Keiichi Kawai; Toru Maruyama; Yasuomi Yamasaki; Yoshinobu Takakura; Masaki Otagiri
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

8.  Plasma pharmacokinetics and tissue disposition of novel dextran-methylprednisolone conjugates with peptide linkers in rats.

Authors:  Suman Penugonda; Hitesh K Agarwal; Keykavous Parang; Reza Mehvar
Journal:  J Pharm Sci       Date:  2010-03       Impact factor: 3.534

9.  Attenuation of acute rejection in a rat liver transplantation model by a liver-targeted dextran prodrug of methylprednisolone.

Authors:  Anjaneya P Chimalakonda; Donald L Montgomery; Jon A Weidanz; Imam H Shaik; Justin H Nguyen; John J Lemasters; Eiji Kobayashi; Reza Mehvar
Journal:  Transplantation       Date:  2006-03-15       Impact factor: 4.939

10.  Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting.

Authors:  M Nishikawa; A Kamijo; T Fujita; Y Takakura; H Sezaki; M Hashida
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.